297 related articles for article (PubMed ID: 22890091)
1. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Chen Y; Yang H; Lu G; Wu X; Huang W; Wu Y; Lv X; Wu G; Zhang G; Li Q; Sun Y
Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091
[TBL] [Abstract][Full Text] [Related]
2. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections.
Carmignani G; De Rose AF; Olivieri L; Salvatori E; Rosignoli MT; Dionisio P
Urol Int; 2005; 74(4):326-31. PubMed ID: 15897698
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
[TBL] [Abstract][Full Text] [Related]
4. Prulifloxacin: a new antibacterial fluoroquinolone.
Prats G; Rossi V; Salvatori E; Mirelis B
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
[TBL] [Abstract][Full Text] [Related]
5. Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections.
Rafailidis PI; Polyzos KA; Sgouros K; Falagas ME
Int J Antimicrob Agents; 2011 Apr; 37(4):283-90. PubMed ID: 21300527
[TBL] [Abstract][Full Text] [Related]
6. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial.
Giannarini G; Mogorovich A; Valent F; Morelli G; De Maria M; Manassero F; Barbone F; Selli C
J Chemother; 2007 Jun; 19(3):304-8. PubMed ID: 17594926
[TBL] [Abstract][Full Text] [Related]
7. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P
Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
[TBL] [Abstract][Full Text] [Related]
8. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Noviello S; Ianniello F; Leone S; Esposito S
Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, comparative study of levofloxacin and ofloxacin in the treatment of complicated urinary tract infections.
Peng MY
J Microbiol Immunol Infect; 1999 Mar; 32(1):33-9. PubMed ID: 11561568
[TBL] [Abstract][Full Text] [Related]
10. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
Peterson J; Kaul S; Khashab M; Fisher A; Kahn JB
Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
[TBL] [Abstract][Full Text] [Related]
11. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent.
Giannarini G; Tascini C; Selli C
Future Microbiol; 2009 Feb; 4(1):13-24. PubMed ID: 19207096
[TBL] [Abstract][Full Text] [Related]
12. Prulifloxacin.
Keam SJ; Perry CM
Drugs; 2004; 64(19):2221-34; discussion 2235-6. PubMed ID: 15456336
[TBL] [Abstract][Full Text] [Related]
13. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Gualco L; Schito AM; Schito GC; Marchese A
Int J Antimicrob Agents; 2007 Jun; 29(6):679-87. PubMed ID: 17363225
[TBL] [Abstract][Full Text] [Related]
15. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
16. Prulifloxacin vs Levofloxacin for Exacerbation of COPD after Failure of Other Antibiotics.
Giusti M; Blasi F; Iori I; Mazzone A; Sgambato F; Politi C; Colagrande P; Casali A; Valerio A; Gussoni G; Bonizzoni E; Campanini M
COPD; 2016 Oct; 13(5):555-60. PubMed ID: 27027547
[TBL] [Abstract][Full Text] [Related]
17. Cefdinir versus levofloxacin in patients with acute rhinosinusitis of presumed bacterial etiology: a multicenter, randomized, double-blind study.
Henry DC; Kapral D; Busman TA; Paris MM
Clin Ther; 2004 Dec; 26(12):2026-33. PubMed ID: 15823766
[TBL] [Abstract][Full Text] [Related]
18. Role of prulifloxacin in the treatment of acute rhinosinusitis.
Passali D; Crisanti A; Bellussi LM
Infez Med; 2015 Dec; 23(4):301-6. PubMed ID: 26700078
[TBL] [Abstract][Full Text] [Related]
19. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
20. Clinical and microbiological efficacy of prulifloxacin for the treatment of chronic bacterial prostatitis due to Chlamydia trachomatis infection: results from a prospective, randomized and open-label study.
Cai T; Mazzoli S; Addonisio P; Boddi V; Geppetti P; Bartoletti R
Methods Find Exp Clin Pharmacol; 2010; 32(1):39-45. PubMed ID: 20383345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
